title: Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population.
abstract: BACKGROUND
  Rs11614913 is a polymorphism in hsa-miR-196a2 reported to alter mature microRNA expression and function. This single-nucleotide polymorphism (SNP) was reported to be associated with susceptibility and prognosis of lung cancer.
  
  
  METHODS
  In this article, association study was performed to reveal the relation between SNP and response rate or severe toxicity after platinum-based regimen in advanced nonsmall cell lung cancer patients.
  
  
  RESULTS
  By screening this polymorphism in 442 Chinese patients with MALDI-TOF Mass Spectrometer, significantly higher occurrence of grade 3 or 4 overall toxicity (P = 0.02) in response to treatment was found in patients with homozygous CC. After stratified analyses, association between rs11614912 and overall toxicity existed, especially in individuals treated with gemcitabine (P = 0.006) or cisplatin (P = 0.008), and in male patients (P = 0.02) or younger patients (P = 0.01).
  
  
  CONCLUSIONS
  Our study confirmed that rs11614913 in hsa-miR-196a2 was associated with severe toxicity in lung cancer patients, and might help to improve individualized therapy in the future.
authors.affiliation: School, of Life Science, East China Normal University, 3663 North Zhongshan Road, Shanghai, P. R., China.
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Zhan
authors.forename: Wenting
authors.initials: W
authors.lastname: Wu
authors.forename: Baohui
authors.initials: B
authors.lastname: Han
authors.forename: Ge
authors.initials: G
authors.lastname: Gao
authors.forename: Rong
authors.initials: R
authors.lastname: Qiao
authors.forename: Juan
authors.initials: J
authors.lastname: Lv
authors.forename: Shuyu
authors.initials: S
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Weiwei
authors.initials: W
authors.lastname: Fan
authors.forename: Hongyan
authors.initials: H
authors.lastname: Chen
authors.forename: Tianbao
authors.initials: T
authors.lastname: Zhang
authors.forename: Aiqin
authors.initials: A
authors.lastname: Gu
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Qihan
authors.initials: Q
authors.lastname: Wu
authors.forename: Daru
authors.initials: D
authors.lastname: Lu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D002681:China; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D017671:Platinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D020641:Polymorphism, Single Nucleotide
chemical_list: C542543:MIRN196 microRNA, human; D035683:MicroRNAs; D017671:Platinum Compounds